Sarepta (SRPT), in a letter dated August 14 to the FDA, responded to the Citizen Petition related to Elevidys. The letter states in part: “The Petition misrepresents the number of treatment-related ...

We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week’s top performers. Arrowhead Pharmaceuticals soared by ...

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment died ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it ...

Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...

Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for one of its medications.

Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options become available today, for the July 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its experimental gene therapies. The company confirmed that a 51-year-old, non ...